Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

被引：0
|
作者：
Thomas Semrad
Afsaneh Barzi
Heinz-Josef Lenz
Irene M. Hutchins
Edward J. Kim
I-Yeh Gong
Michael Tanaka
Laurel Beckett
William Holland
Rebekah A. Burich
Leslie Snyder-Solis
Philip Mack
Primo N. Lara
机构：
[1] University of California Davis Comprehensive Cancer Center,Division of Hematology/Oncology, Department of Internal Medicine
[2] University of Southern California Norris Cancer Center,Medical Oncology, Keck School of Medicine
[3] University of California,Department of Internal Medicine
[4] Davis,Division of Biostatistics, Department of Public Health Sciences
[5] University of California,undefined
[6] Davis,undefined
来源：
International Journal of Clinical Oncology | 2015年 / 20卷
关键词：
Gemcitabine; Erlotinib; Pancreatic cancer; Pharmacodynamic separation; KRAS mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：518 / 524
页数：6
相关论文
共 50 条
  • [21] Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors
    Sezgin, C
    Karabulut, B
    Uslu, R
    Sanli, UA
    Goksel, G
    Yuzer, Y
    Goker, E
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2005, 40 (12) : 1486 - 1492
  • [22] Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
    Melnik, Marianne K.
    Webb, Craig P.
    Richardson, Patrick J.
    Luttenton, Charles R.
    Campbell, Alan D.
    Monroe, Thomas J.
    O'Rourke, Timothy J.
    Yost, Kathleen J.
    Szczepanek, Connie M.
    Bassett, Michelle R.
    Truszkowski, Kimberly J.
    Stein, Phyllis
    Van Brocklin, Matthew W.
    Davis, Alan T.
    Bedolla, Gabriela
    Vande Woude, George F.
    Koo, Han-Mo
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (08) : 2423 - 2429
  • [23] A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
    Jo, Jung Hyun
    Jung, Dawoon E.
    Lee, Hee Seung
    Park, Soo Been
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Cho, Sangsook
    Song, Si Young
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (09) : 1565 - 1577
  • [24] Management of Advanced Pancreatic Cancer with Gemcitabine Plus Erlotinib: Efficacy and Safety Results in Clinical Practice
    Diaz Beveridge, Robert
    Alcolea, Vicent
    Aparicio, Jorge
    Segura, Angel
    Garcia, Jose
    Corbellas, Miguel
    Fonfria, Maria
    Gimenez, Alejandra
    Montalar, Joaquin
    JOURNAL OF THE PANCREAS, 2014, 15 (01): : 19 - 24
  • [25] Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer
    von der Maase, H.
    EUROPEAN JOURNAL OF CANCER, 2000, 36 : S13 - S16
  • [26] Gemcitabine for unresectable, locally advanced or metastatic bladder cancer
    Shelly, M.
    Cleves, A.
    Wilt, T. J.
    Mason, M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (04):
  • [27] Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study
    Richards, Donald A.
    Kuefler, Paul R.
    Becerra, Carlos
    Wilfong, Lalan S.
    Gersh, Robert H.
    Boehm, Kristi A.
    Zhan, Feng
    Asmar, Lina
    Myrand, Scott P.
    Hozak, Rebecca R.
    Zhao, Luping
    Gill, John F.
    Mullaney, Brian P.
    Obasaju, Coleman K.
    Nicol, Steven J.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (01) : 144 - 153
  • [28] Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study
    Donald A. Richards
    Paul R. Kuefler
    Carlos Becerra
    Lalan S. Wilfong
    Robert H. Gersh
    Kristi A. Boehm
    Feng Zhan
    Lina Asmar
    Scott P. Myrand
    Rebecca R. Hozak
    Luping Zhao
    John F. Gill
    Brian P. Mullaney
    Coleman K. Obasaju
    Steven J. Nicol
    Investigational New Drugs, 2011, 29 : 144 - 153
  • [29] Efficacy and toxicity of gemcitabine-erlotinib in the metastatic pancreatic cancer treatment
    Mejia, L.
    Vicente, I.
    Lopez, M.
    Antonino, G.
    Garcia del Busto, N.
    Sanchez, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 989 - 989
  • [30] Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
    Daniel Habermehl
    Kerstin Kessel
    Thomas Welzel
    Holger Hof
    Amir Abdollahi
    Frank Bergmann
    Stefan Rieken
    Jürgen Weitz
    Jens Werner
    Peter Schirmacher
    Markus W Büchler
    Jürgen Debus
    Stephanie E Combs
    Radiation Oncology, 7
12345